Related Experiment Video
Updated: Jan 4, 2026
Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma
Published on: November 11, 2021
Prognostic Impact of CD44 Expression in Patients With Myxofibrosarcoma
Hiroyuki Tsuchie1, Makoto Emori2, Naohisa Miyakoshi3
1Department of Orthopedic Surgery, Akita University Graduate School of Medicine, Akita, Japan tuchikiti@yahoo.co.jp.
Background/Aim:
Abnormal expression of CD44 may promote cancer invasion. However, a limited number of studies have investigated the expression of CD44 in soft tissue sarcoma such as myxofibrosarcoma. We evaluated the relationship between expression of the standard form of CD44 (CD44s) and the clinical course of myxofibrosarcoma.
Materials And Methods:
Forty-four myxofibrosarcoma patients were retrospectively enrolled. Patient information including the proportion of CD44s-positive cells was collected, and multivariate analyses were conducted to determine the relationship between CD44s expression and clinicopathological factors.
Results:
Although CD44s did not affect prognosis, multivariate analysis indicated that high expression of CD44s predicted poor event-free survival (p=0.004) and local recurrence (p=0.049). CD44s expression was not associated with the occurrence of distant metastasis but was significantly higher in those with lung metastasis (p=0.044).
Conclusion:
Increased expression of CD44s predicted poor event-free survival and local recurrence and was observed in myxofibrosarcoma patients with lung metastasis.
